Karyopharm Therapeutics Inc. announced the expansion of its royalty agreement with entities managed by HealthCare Royalty Management, LLC for up to $100 million in new financing to support the ongoing development and commercialization of XPOVIO®, the Company’s first-in-class, oral Selective Inhibitor of Nuclear Export compound, and for the clinical development of Karyopharm’s other programs, including eltanexor.
June 24, 2021
· 7 min read